ACADIA Pharmaceuticals Inc. (ACAD)
| Market Cap | 2.69B |
| Revenue (ttm) | 512.40M |
| Net Income (ttm) | -204.62M |
| Shares Out | 161.84M |
| EPS (ttm) | -1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 826,894 |
| Open | 16.45 |
| Previous Close | 16.28 |
| Day's Range | 16.45 - 17.14 |
| 52-Week Range | 12.24 - 28.06 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 19.25 (+15.9%) |
| Earnings Date | Nov 7, 2022 |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 d... [Read more...]
Financial Performance
In 2021, ACAD's revenue was $484.15 million, an increase of 9.60% compared to the previous year's $441.76 million. Losses were -$167.87 million, -40.38% less than in 2020.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 19.25, which is an increase of 15.93% from the latest price.
News
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepte...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinet...
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Fi...
Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...
Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022. “In the second quarter of 2022, NUPLAZID net sal...
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pima...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) reg...
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. fi...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals ...
NEW YORK , July 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of i...
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trof...
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive ...
ATLANTA--(BUSINESS WIRE)---- $ACAD #Alzamend--Alzamend Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depression, and Post-Traumatic Stress Disorder
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.
Why Acadia Pharmaceuticals Stock Is Crashing Today
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Why Acadia Pharma Shares Are Plunging Today
A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The d...
Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote
Shares of Acadia Pharmaceuticals Inc. ACAD, +3.94% were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the compa...
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meet...
Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's di...
Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a tre...
Acadia Pharmaceuticals Stock Trading Halted Today
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company's common stock. The U.S. Food and Drug Administration's Psychopharmac...